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Abstract 
Background: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease commonly associated with obesity, 
type 2 diabetes, and inflammation-all features of insulin resistant syndrome. However, very limited data are available 
regarding the association of subclinical inflammation and insulin resistance with NAFLD in a prediabetic state. We, 
therefore, conducted the study to assess this relationship among this population.
Methods: We studied a cross-sectional analytical design of 140 [male/female, 77/63; age in years (ranges), 45 (25–68)] 
prediabetic subjects after confirming with 75 g oral glucose tolerance test. The diagnosis of NAFLD was made by 
ultrasonic examination of the liver and divided into groups of without NAFLD (n = 63) and NAFLD (n = 77). All indi-
viduals underwent anthropometric and clinical examinations. Among laboratory investigations, serum glucose was 
estimated by glucose oxidase method, serum lipid profile and liver enzymes were measured by the enzymatic col-
orimetric method and glycated hemoglobin was measured by high performance liquid chromatography technique. 
Serum insulin and high sensitivity C reactive protein (hsCRP) were measured by enzyme immunoassay technique. 
Insulin resistance (HOMA-IR) was calculated by homeostasis model assessment (HOMA).
Results: There was significantly higher levels of hsCRP (2.82 ± 1.60 vs. 1.39 ± 0.66 mg/l, P < 0.001) and HOMA-IR 
(4.03 ± 1.39 vs. 1.98 ± 1.04, P < 0.001) in NAFLD subjects compared to their without NAFLD counterparts. hsCRP 
[odds ratio (OR) = 5.888, 95 % confidence interval (CI) 2.673–12.970, P < 0.001] and HOMA-IR (OR = 4.618, 95 % CI 
2.657–8.024, P < 0.001) showed significant determinants of NAFLD after potential confounders of body mass index 
and triglyceride were adjusted.
Conclusions: Subclinical chronic inflammation and insulin resistance seem to be independent mediators of the 
association between NAFLD and prediabetes. The data also indicate that the inflammatory condition and insulin 
resistance are associated with each other and these, in turn, are affected by adiposity and dyslipidemia in prediabetic 
subjects.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The entity of ‘prediabetes’, termed by WHO as ‘impaired 
glucose regulation (IGR)’ is now being recognized as 
a constellation of three different disorders which may 
have different isolated or combined pathophysiologi-
cal characteristics. A study from BIRDEM has shown 
that Bangladeshi prediabetic population may be catego-
rized into three groups based on their pathophysiological 
mechanism [1]. These are isolated impaired fasting glu-
cose (I-IFG), isolated impaired glucose tolerance (I-IGT) 
and a combination of both defects (IFG–IGT). Since 
insulin resistance (IR) is associated with the majority of 
the subjects in the IGR and since this state is known to 
be associated with increased cardiovascular morbidity 
and mortality [2], it is imperative to investigate this group 
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for the development of nonalcoholic fatty liver disease 
(NAFLD).
NAFLD is becoming a major public health problem all 
over the world with increasing incidence of diabetes mel-
litus, hypertension, dyslipidemia, hepatic steatosis and 
metabolic syndrome (MS). The prevalence of the disease 
is expected to increase worldwide and the trend in devel-
oping countries is switching towards western lifestyles. 
The exact etiology of NAFLD is not yet known, but IR 
is the key mechanism most commonly associated with 
the pathogenesis of this disorder. This, in turn, seems 
to create a linkage between NAFLD and type 2 diabe-
tes (T2DM) by subclinical inflammation as a key factor 
[3]. Although the role of IR in the relationship between 
subclinical inflammation and NAFLD among the T2DM 
subjects is fairly well established [2], however, examin-
ing this association in a prediabetic state is limited. One 
study has been done in an urban population of South 
India and they showed a higher prevalence of NAFLD 
(54.5  %) among the T2DM subjects compared to those 
with prediabetes (IFG or IGT) (33  %), I-IGT (32.4  %), 
I-IFG (27.3  %) and normal glucose tolerance (NGT) 
(22.5 %) [4]. However, they did not see the association of 
IR and subclinical inflammation as a reproducible factor 
in the development of NAFLD.
The pathogenesis of NAFLD leading to metabolic 
abnormalities has not been fully elucidated. It is char-
acterized by excessive accumulation of free fatty acid 
within the liver where they are reesterified with glycerol 
to produce triglyceride (TG). This lipid abnormality leads 
to the condition of IR by alterations in insulin receptors 
of peripheral tissues. Increased deposition of fatty acids 
within the hepatocytes causes oxidative stress with the 
release of free radicals leading to ATP depletion, mito-
chondrial dysfunction and hepatic injury-all contribute 
to the development of inflammation followed by fibro-
sis [5]. The hepatic steatosis caused by oxidative stress 
and their underlying mechanism for the development 
of inflammation still remains unclear. Recent studies 
revealed that defective insulin action reduces the lipolysis 
of hepatic fat by decreasing β-oxidation which enhances 
the release of nonesterified fatty acid (NEFA) from adi-
pose tissue so that more NEFA are transported through 
the bloodstream and taken up by the liver. In a secondary 
event of hepatic fat accumulation causes oxidative stress 
and mitochondrial dysfunction thereby releasing of reac-
tive oxygen species (ROS) through lipid peroxidation and 
the generation of proinflammatory cytokines leading to 
inflammation [6].
High sensitivity C reactive protein (hsCRP), a proin-
flammatory cytokine released during the condition of 
nonalcoholic steatohepatitis (NASH), also a sensitive 
marker of systemic inflammation, has been shown to be 
increased in a hyperglycemic sate. Serum hsCRP levels 
are elevated in subjects with prediabetes or T2DM. Prior 
clinical studies showed increased levels of hsCRP as a sig-
nificant risk factor for the progression of future diabetes 
[7]. Relationship of inflammatory cytokines with elevated 
blood glucose levels and the role of IR for this associa-
tion are available. However, it remains unclear whether a 
relationship exists between hsCRP and IR with NAFLD 
in a prediabetic state. Nevertheless, data relating the 
association of subclinical inflammation with NAFLD in 
prediabetes is limited, therefore, we hypothesized that a 
high proportion of prediabetic subjects develop NAFLD 




A cross-sectional analytical study with group comparison 
design was conducted during November 2012 to March 
2013 in a diabetes care Hospital in Bangladesh (BIR-
DEM) and a total number of 140 (one hundred and forty) 
prediabetic subjects were recruited in the study. Diabetes 
and prediabetes were diagnosed following WHO Group 
Study criteria [8]. Of the total, upper abdomen ultra-
sonogram had done and the subjects were divided into 
77 without NAFLD and 63 NAFLD groups. We excluded 
subjects with known liver diseases like viral hepati-
tis, hepatobiliary diseases, malignancies, inflammatory 
bowel disease, current medication with lipid and glucose 
lowering drugs, chronic cardiac, renal and respiratory 
diseases, stroke, type 1 diabetes, recent change (≥10 %) 
in body weight and pregnant women. All subjects under-
went anthropometric measurements of body weight, 
height, waist and hip circumference (WC and HC), sys-
tolic and diastolic blood pressures (SBP and DBP) were 
measured by standard procedures. Body mass index 
(BMI) of the subjects was calculated using the formula of 
BMI = Weight (kg)/Height (m2).
Biochemical analysis
After overnight fasting (8–14  h) study subjects under-
went fasting blood sampling by venipuncture to assess 
the biochemical tests including fasting and postprandial 
serum glucose, glycosylated hemoglobin (HbA1c), total 
cholesterol (TC), triglyceride (TG), and high density 
lipoprotein cholesterol (HDL-c), glutamate oxaloacetate 
transaminase (GOT), glutamate pyruvate transami-
nase (GPT), gamma glutamate transaminase (GGT) and 
alkaline phosphatase (ALP). All tests were measured by 
standard laboratory methods using a conventional auto-
mated analyzer (Dimension® clinical chemistry system, 
Siemens Healthcare Diagnostics Inc. USA). Low den-
sity lipoprotein cholesterol (LDL-c) was calculated by 
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Friedwald formula [9]. Serum insulin and hsCRP were 
determined by ELISA technique using commercial kits 
(DRG-International, Germany) and their optical density 
(OD) were measured by ELISA plate reader (Multiscan 
FC, USA). The inter- and intra-assay coefficient of vari-
ation (% CV) for FSG, insulin and hsCRP were 3.35, 4.33 
and 5.12 % and 2.1, 3.11 and 4.01 % respectively. Winter-
green method was used to determine the blood erythro-
cyte sedimentation rate (ESR) [10]. Homeostatic model 
assessment insulin sensitivity (HOMA  %S) and pancre-
atic β-cell function (HOMA %B) was derived from fasting 
values of serum glucose and insulin. Homeostatic model 
assessment insulin resistance (HOMA-IR) was calcu-
lated according to the HOMA model formula: HOMA-
IR  =  fasting insulin  ×  fasting glucose, divided by 22.5 
[11]. Total body fat was determined by bioimpedometry.
Radiological evaluations
Ultrasound imaging of the liver was carried out by a 
trained radiologist who was blinded of the aims of the 
study using a high resolution sonography machine 
(Philips Ultrasound-Ay-MNT-15 TTK, HDI-4000, Neth-
erland) having a 3.5 MHz linear transducer frequency in 
fasting state of the subjects to assess the degree of stea-
tosis. The presence of fatty liver was confirmed in the 
absence of alcohol intake by comparative assessment of 
echoes brightness arising from the hepatic parenchyma 
with a high level of liver-kidney differentiation, the 
entrance of echoes into the deepest part of the liver and 
clear images of the liver blood vessels. NAFLD evaluation 
was based on scoring the scale as Grade 0: absent (nor-
mal echogenicity), Grade 1: mild steatosis, Grade 2: mod-
erate steatosis, Grade 3: severe steatosis [12].
Statistical analysis
Data of all parameters were presented as the 
mean  ±  standard deviation (SD) or number as appro-
priate. Comparison of mean values between two groups 
was tested using student’s unpaired T test. According 
to the distribution of data, we used the natural logarith-
mic transformation of the ESR skewed values for statis-
tical analysis [13, 14]. The sample size was calculated by 
using the regression model for individual predictors and 
it depends on the desired power (l−α), significance level 
(α), the number of predictors and the expected effect 
sizes. Sampling weights were used by using the formula 
of N > 50 +  8 m, where m is the number of independ-
ent variables (IVs) for testing the multiple correlation 
and N  >  104 +  m for testing individual predictors [15]. 
In our study, there were four IVs (Table  3) and the cal-
culated sample number was 50 +  8 (4) =  82 cases and 
104  +  4  =  108 cases for testing individual predictors. 
These calculations were based on significance level of 5 % 
(α = 0.05) and 80 % power (P = 0.20). Pearson’s regres-
sion curve was done to see the correlation of hsCRP 
with IR in the study subjects. A multiple linear regres-
sion analysis was done to investigate the relationship of 
HOMA-IR with hsCRP in NAFLD subjects after adjust-
ing the effects of major confounding variables of BMI, 
WHR, TG, and hsCRP respectively. Multivariate logistic 
regression was used to predict significant determinants 
of NAFLD (without NAFLD considered as reference) 
as the dependent variable and BMI, TG, HOMA-IR and 
hsCRP as independent variables. To evaluate the effects 
of HOMA-IR and hsCRP with NAFLD, adjusted odds 
ratio (ORs) and 95 % confidence interval (CI) estimated 
by controlling the other significant predictors of NAFLD 
[16]. A P < 0.05 was considered as statistically significant. 
All statistical measures were performed using statistical 
package for social science (SPSS) for windows version 
17.0 (SPSS Inc., Chicago, IL, USA).
Results
The general characteristics of the prediabetic subjects 
are shown in Table  1. Of the 140 subjects, 54 had IFG 
(38.6 %, M/F 35/19), 36 had IGT (25.7 %, 12/24) and 50 
had IFG-IGT (35.7  %, 30/20) respectively. After liver 
ultrasound, 63 had NAFLD (45  %, 35/28) and 77 had 
without NAFLD (55 %, 42/35) respectively. Among fatty 
liver severity, 73 (52.1  %) had grade 0, 50 (35.7  %) had 
grade 1, 14 (10.0 %) had grade 2 and 3 (2.1 %) had grade 
3 steatosis. Subjects with prediabetes had higher lev-
els of hsCRP, ESR and HOMA-IR. Sociodemographic, 
anthropometric, clinical and biochemical characteristics 
of the study subjects according to their fatty liver group 
are shown in Table 2. Prediabetic subjects with NAFLD 
had significantly higher levels of WC (P = 0.034), WHR 
(P  =  0.004), SBP (P  =  0.011), PPSG (P  =  0.042), TC 
(P = 0.010), TG (P = 0.047), LDL-c (P = 0.014), SGOT 
(P =  0.026), GGT (P =  0.003), hsCRP (P  <  0.001), log 
ESR (P =  0.001), FSI (P  <  0.001), PPSI (P  <  0.001) and 
HOMA-IR (P  <  0.001) compared to without NAFLD 
group. On the other hand, prediabetic subjects with 
NAFLD, showed significantly lower levels of HDL-c 
(P  =  0.024), HOMA  %S (P  ≤  0.001) and HOMA  %B 
(P  =  0.007) as compared to their without NAFLD 
counterparts.
Regression curve analysis showed significant posi-
tive correlation of HOMA-IR with hsCRP (r2  =  0.034, 
P = 0.030) in the total study subjects (Fig. 1).
Association of HOMA-IR with hsCRP in NAFLD sub-
jects are shown in Table 3. In multiple linear regression 
analysis, HOMA-IR showed significant positive associa-
tion with BMI (β = 0.294, P = 0.016), WHR (β = 0.259, 
P = 0.036) and hsCRP (β = 0.262, P = 0.034) after adjust-
ing the effect of major confounder of TG.
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Association of hsCRP and HOMA-IR with NAFLD 
group considering without NAFLD as reference after 
adjusting the effects of major confounding variables are 
shown in Table  4. In binary logistic regression analysis, 
hsCRP (OR  =  5.888, CI 2.673–12.970, P  <  0.001) and 
HOMA-IR (OR = 4.618, 95 % CI 2.657–8.024, P < 0.001) 
were found to be significant determinants of NAFLD 
after adjusting the effects of major confounding variables 
of BMI and TG respectively.
Discussion
The study demonstrates the first cross-sectional study 
where the relationship between subclinical inflamma-
tion and IR with NAFLD has been evaluated among 
Bangladeshi prediabetic subjects. In this study, 44  % 
Table 1 General characteristic of the study subjects
Results are expressed as number (percentage), mean ± SD; level of significance 
was calculated by Student’s‘t’ test; n number of subjects
Parameter Prediabetic subjects 
(n = 140)
Sex [n (%)]
 Male 77 (55.0)
 Female 63 (45.0)
Age (years) 45.4 ± 9.4
BMI (kg/m2) 26.06 ± 4.51
WC (cm) 90.4 ± 8.2
HC (cm) 96.3 ± 8.7
WHR 0.93 ± 0.04
% BF 29.7 ± 7.4
SBP (mmHg) 120 ± 23
DBP (mmHg) 82 ± 20
Different subgroups of prediabetes [n (%)]
 IFG 54 (38.6)
 IGT 36 (25.7)
 IFG-IGT 50 (35.7)
NAFLD evaluation [n (%)]
 Without NAFLD 77 (55.0)
 With NAFLD 63 (45.0)
 Grade 0 73 (52.1)
 Grade 1 50 (35.7)
 Grade 2 14 (10.0)
 Grade 3 3 (2.1)
FSG (mmol/l) 5.86 ± 0.45
PPSG (mmol/l) 8.15 ± 1.51
HbA1c (%) 5.85 ± 0.56
TC (mg/dl) 193 ± 39
TG (mg/dl) 163 ± 80
HDL-c (mg/dl) 37 ± 7
LDL-c (mg/dl) 122 ± 35
GOT (IU/l) 31 ± 16
GPT (IU/l) 35 ± 16
GGT (IU/l) 32 ± 14
ALP (IU/l) 102 ± 27
HsCRP (mg/l) 2.04 ± 1.37
log ESR (mm/h) 1.31 ± 0.22
FSI (µIU/ml) 11.26 ± 7.14
PPSI (µIU/ml) 68 ± 41
HOMA %S 55 ± 21
HOMA %B 120 ± 35
HOMA-IR 2.91 ± 1.58
Table 2 Sociodemographic, clinical, anthropometric and   
biochemical indexes of  prediabetic subjects without  and 
with NAFLD
Results are expressed as number (percentage), mean ± SD; n = number of 
subjects; the level of significance at P < 0.05





Different subgroups of prediabetes [n (%)]
 IFG 33 (42.9) 21 (33.3) –
 IGT 20 (26.0) 16 (25.4) –
 IFG-IGT 24 (31.2) 26 (41.3) –
Gender [n (%)]
 Male 35 (55.6) 42 (54.5) –
 Female 28 (44.4) 35 (45.5) –
Age (years) 44.2 ± 9.4 46.1 ± 9.2 −1.666/0.098
BMI (kg/m2) 25.54 ± 4.75 26.68 ± 4.16 −1.489/0.139
WC (cm) 89 ± 8 92 ± 8 −2.137/0.034
HC (cm) 95 ± 9 97 ± 8 −1.038/0.301
WHR 0.93 ± 0.04 0.94 ± 0.04 −2.098/0.038
% BF 29.1 ± 7.2 30.5 ± 7.6 −1.094/0.276
SBP (mmHg) 115 ± 18 126 ± 25 −2.899/0.004
DBP (mmHg) 78 ± 18 87 ± 20 −2.562/0.011
FSG (mmol/l) 5.88 ± 0.49 5.84 ± 0.41 0.534/0.594
PPSG (mmol/l) 7.92 ± 1.51 8.44 ± 1.47 −2.049/0.042
HbA1c (%) 5.81 ± 0.62 5.89 ± 0.47 −0.879/0.381
TC (mg/dl) 185 ± 37 202 ± 40 −2.603/0.010
TG (mg/dl) 151 ± 72 177 ± 88 −1.925/0.047
HDL-c (mg/dl) 38 ± 7 35 ± 7 2.282/0.024
LDL-c (mg/dl) 116 ± 32 130 ± 36 −2.488/0.014
GOT (IU/l) 28 ± 12 34 ± 18 −2.255/0.026
GPT (IU/l) 33 ± 16 37 ± 17 −1.780/0.077
GGT (IU/l) 28 ± 14 36 ± 13 −3.059/0.003
ALP (IU/l) 103 ± 27 100 ± 26 0.516/0.606
HsCRP (mg/l) 1.39 ± 0.66 2.82 ± 1.60 −7.098/<0.001
log ESR (mm/h) 1.25 ± 0.20 1.38 ± 0.22 −3.393/0.001
FSI (µIU/ml) 6.83 ± 2.68 16.68 ± 7.17 −11.132/<0.001
PPSI (µIU/ml) 55 ± 38 83 ± 40 −4.294/<0.001
HOMA %S 59 ± 24 48 ± 15 3.310/<0.001
HOMA %B 127 ± 36 111 ± 32 2.721/0.007
HOMA-IR 1.98 ± 1.04 4.03 ± 1.39 −9.923/<0.001
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of the prediabetic subjects were affected by NAFLD 
after liver ultrasound scanning which is in accordance 
with the prior clinical studies [17, 18] where prevalence 
also higher, however, their study subjects were previ-
ously detected NAFLD from where the prevalence 
was calculated. Although conventional view holds that 
NAFLD is directed related to IR and pre-diabetes, emerg-
ing evidence indicate that a direct cause-effect relation-
ship may not exist between these pathological conditions 
[19]. Nevertheless, very limited data are available regard-
ing the prevalence of NAFLD among the prediabetic 
subjects. Agarwal et  al. [20] showed the prevalence of 
NAFLD after liver ultrasonography among T2DM sub-
jects was 57.2  %. Ruckert et  al. [21] found these higher 
numbers among nondiabetic participants though their 
fatty liver assessment was based on the abnormal con-
centration of liver enzymes. They found the fatty liver 
prevalence in NGT was 18.7 %, IFG 34.6 %, IGT 33.0 %, 
IGT/IFG 33.3 %, NDD 42.5 % and known diabetes 25.8 % 
respectively.
hsCRP is an acute phase reactant protein with a short 
life of around 18  h, and its level is increased during 
NASH causing low-grade systemic inflammation of the 
liver. Because of its pro-inflammatory characteristics, 
hsCRP has been considered as a potential biomarker of 
subclinical inflammation [7]. Recent data from case and 
control studies showed elevated serum levels of hsCRP 
in NAFLD subjects and their association also increased 
with increasing the severity of fatty liver [20, 21]. How-
ever, reports from few studies failed to show the relation-
ship of increased levels hsCRP with the different grades 
of NAFLD. The current study showed higher hsCRP and 
IR levels in the study subjects and their strong association 
with NAFLD compared to the without NAFLD group. 
Our study results are in line with previous cross-sectional 
studies that revealed a strong association between the 
hsCRP and NAFLD in Japanese and Korean Asians [22, 
23]. A case–control study by Koruk et  al. [24] reported 
that measurement of the degrees of hsCRP could be 
used as a simple and sensible technique for the diagno-
sis of NASH and their relationship with histopathological 
findings of the liver. In addition, Yoneda et al. [25] from 
their observational studies reported increased levels of 
hsCRP can be considered the key mechanism of NAFLD 
development and its rapid progression to NASH due to 





















r2 = 0.034 
P = 0.030 
Fig. 1 Relationship of hsCRP with HOMA-IR among the total study 
subjects: serum hsCRP showed significant positive correlation 
(P = 0.030) with HOMA-IR in the study subjects
Table 3 Multiple linear regression analysis using HOMA-IR 
as dependent variable after adjusting the effects of major 
confounders




t value P value 95 % Confidence 
Interval
Lower Upper
BMI (kg/m2) 0.294 2.483 0.016 0.019 0.178
WHR 0.259 2.144 0.036 0.564 16.449
TG (mg/dl) 0.015 0.127 0.899 −0.004 0.004
hsCRP (mg/l) 0.262 −2.167 0.034 −0.440 −0.017
CONSTANT – −1.597 0.116 −13.643 1.536
Table 4 Factors associated with  NAFLD (considering without  NAFLD as  reference) after  adjusting the effects of  major 
confounders by binary logistic regression model
SE standard error, CI confidence interval
Dependent variable: Group (NAFLD vs. without NAFLD as reference); Adjusted R2 = 0.565; the level of significance at P < 0.05
Parameter Regression  
coefficient (β)
SE P value Odds ratio 95 % CI of OR
Lower Upper
BMI (kg/m2) 0.108 0.069 0.117 1.114 0.973 1.276
TG (mg/dl) 0.003 0.003 0.303 1.003 0.997 1.010
hsCRP (mg/l) 1.773 0.403 <0.001 5.888 2.673 12.970
HOMA-IR 1.530 0.282 <0.001 4.618 2.657 8.024
CONSTANT −11.331 2.577 0.000 0.000 – –
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oxidative stress. Conversely, data from Wieckowska et al. 
[26] diverge from our previous findings and they found 
no significant role of hsCRP in the prognosis of NAFLD.
NAFLD is a hepatic manifestation where IR is the key 
factor due to abnormal lipid metabolism which in turn 
progress to hepatic injury caused by oxidative stress. 
The molecular mechanism of IR in the development of 
NAFLD and the role inflammatory cytokines for their 
association is controversial. Recent epidemiological evi-
dence reveals IR as a detrimental factor in the patho-
genesis of NAFLD and progression to future NASH, 
particularly in individuals of obese diabetics and related 
disorders [24]. It has been suggested that genetic factors 
that reduce insulin sensitivity and increase the accumula-
tion of triacylglycerol levels which ultimately responsible 
for the development of IR. Our study supports the asso-
ciation between IR and NAFLD as represented by the 
fact that all the subjects studied are glucose intolerance. 
Several studies showed the relationship between IR and 
NAFLD in subjects with diabetes [24–26] however, this 
is the first study showing the independent roles of IR and 
subclinical inflammation in the development of NAFLD 
among Bangladeshi prediabetic subjects.
The abnormal lipid metabolism in the liver due to IR 
and their consequence in the pathogenesis of NAFLD is 
not well elucidated, excessive accumulation of triglycer-
ides within the hepatocytes induces the release of ROS 
resulting oxidative stress, depletion of mitochondrial 
ATP production, release of pro-inflammatory cytokines-
all of these triggers the subclinical chronic inflamma-
tion. When hepatocellular damage occurs, macrophage 
derived inflammatory cytokines (TNF-α and IL-6) are 
released leading to the production of acute phase reactant 
protein (hsCRP) [26]. Increased levels of serum hsCRP 
reveal the manifestation of IR symptoms like obesity, 
T2DM and cardiovascular morbidity and mortality. Adi-
pose tissue activates the macrophage infiltration thereby 
releasing IL-6 and is closely linked to the production of 
hsCRP, while TNF-α only show its strong relation with 
IR occurring both in intra-abdominal and subcutaneous 
tissues [27, 28]. The pathology of NAFLD in the context 
of obesity is complicated. It appears that dysregulated 
adipose remodeling and its subsequent chronic inflam-
mation can be considered as the key etiological factors 
in the development of fatty liver demonstrated from the 
experimental observations in ob/ob mice after induc-
tion of a high-fat diet [29, 30]. However, NAFLD itself 
is a cause or consequence of IR is not well determined. 
The lipotoxicity effect of liver impairs the insulin action 
resulting hyperinsulinemia and subsequent leads to the 
condition of oxidative stress following chronic inflamma-
tion and fibrosis. The association between hsCRP and IR 
with NAFLD also remained consistent by binary logistic 
regression analysis when other covariates are adjusted, 
which reinforces the concept that IR is the consequence 
of hepatic fat accumulation that in turn leads to the 
development of subclinical inflammation among predia-
betic subjects.
The study has several limitations and recommenda-
tions. NAFLD examination was done by ultrasonography 
imaging of the liver but not by liver biopsy which consid-
ered as the gold standard method. Correlation between 
the different stages of NAFLD (by the histologic picture) 
and the levels of serum inflammatory markers could not 
be done. Among inflammatory cytokines, the diagno-
sis of serum hsCRP provides the most promising results 
revealed by several cross-sectional studies, however, 
epidemiological study from larger cohort of prediabe-
tes having NAFLD should be considered to reformulate 
the relationship between serum inflammatory mark-
ers with insulin resistance and their causal association 
with NAFLD. It is an analytical study with a cross-sec-
tional design thus; no causal association between hsCRP 
and other interacting molecules with NAFLD could be 
explored.
Conclusions
From the above study, it may conclude that a high pro-
portion (more than one-third) of the prediabetic subjects 
has NAFLD and the distribution of the disorder is almost 
similar in various subgroups of prediabetes. Insulin 
resistance followed by subclinical chronic inflammation 
can be considered as key factors in the pathogenesis of 
NAFLD among prediabetic subjects. The data also indi-
cate that the inflammatory condition and insulin resist-
ance are associated with each other and those, in turn, 
are affected by adiposity and dyslipidemia in prediabetic 
subjects.
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sedimentation rate; FSI: fasting serum insulin; PPSI: postprandial serum insulin; 
HOMA %S: insulin sensitivity assessed by homeostasis model assessment; 
HOMA %B: β cell function assessed by homeostasis model assessment; 
HOMA-IR: homeostasis model assessment insulin resistance.
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